MET and colorectal carcinoma: To date, no severe adverse events have been reported for these agents, although some patients complained about fatigue, poor appetite, allergic reactions, edema, skin rash, and neutropenia.252,266 There are several current clinical trials of HGF/c-MET-targeted agents in the context of CRC therapy (Table 5).